Trends in HU utilization and cerebrovascular outcomes before and after publication of the 2014 National Heart, Lung, and Blood Institute sickle cell disease guidelines.
Publication/Presentation Date
12-13-2025
Abstract
The 2014 National Heart, Lung, and Blood Institute (NHLBI) guidelines recommend offering hydroxyurea to all patients with sickle cell disease SS/Sβ0 (SCD) aged ≥ 9 months. The relationship between early hydroxyurea initiation and the development of cerebrovascular disease (CVD) is unclear. This retrospective study describes trends in HU prescriptions and CVD outcomes in patients with SCD SS/Sβ
First Page
1
Last Page
8
ISSN
1521-0669
Published In/Presented At
Dain, A. S., Li, Y., Master, S., Bailey, C. L., Vossough, A., Ichord, R. N., Raffini, L., Getz, K., & Kwiatkowski, J. L. (2025). Trends in HU utilization and cerebrovascular outcomes before and after publication of the 2014 National Heart, Lung, and Blood Institute sickle cell disease guidelines. Pediatric hematology and oncology, 1–8. Advance online publication. https://doi.org/10.1080/08880018.2025.2579978
Disciplines
Medicine and Health Sciences | Pediatrics
PubMedID
41388752
Department(s)
Department of Pediatrics
Document Type
Article